Weight management for overweight endometrial cancer patients undergoing fertility-sparing treatment
Weight Management in Overweight Endometrial Cancer Patients Undergoing Fertility-sparing Treatment
This study tests if a weight management program can help overweight women with endometrial cancer who want to preserve their fertility feel better and improve their treatment results.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 240 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Peking University People's Hospital Academic / other |
| Locations | 1 site (Beijing, China) |
| Trial ID | NCT06169449 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of a systematic weight management program on overweight and obese patients with endometrial cancer who are receiving fertility-sparing therapy. Participants are randomly assigned to either a weight management group, which includes diet, exercise, and support, or a control group receiving routine care. The study collects data on body morphology, glycolipid metabolism, and tumor outcomes to evaluate the effectiveness and safety of the weight management intervention. The goal is to determine if weight management can improve treatment outcomes for these patients.
Who should consider this trial
Good fit: Ideal candidates are overweight or obese individuals aged 18 and older diagnosed with endometrial cancer or atypical hyperplasia who are seeking fertility-preserving treatment.
Not a fit: Patients with severe medical complications, communication barriers, or who are pregnant may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance treatment outcomes and fertility preservation for overweight and obese patients with endometrial cancer.
How similar studies have performed: While there is a lack of prospective studies specifically targeting weight management in this context, retrospective studies suggest that obesity negatively impacts treatment outcomes in endometrial cancer.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * age ≥18 years old * diagnosed as endometrial cancer or atypical hyperplasia * immunohistochemical staining and sequencing of pathological tissue * fertility-preserving therapy * BMI≥25 kg/m2 * informed consent. Exclusion Criteria: * those with communication barriers * pregnant women * medical and surgical serious complications: urinary calculi, history of renal failure or severe renal insufficiency, familial dyslipidemia, severe liver disease, chronic metabolic acidosis, history of pancreatitis, severe diabetes mellitus, active gallbladder disease, fat dyspepsia, severe cardiovascular and cerebrovascular diseases.
Where this trial is running
Beijing, China
- Peking University People's Hospital — Beijing, China, China (Recruiting)
Study contacts
- Study coordinator: Xiaodan Li, Master
- Email: lxd_2000_510@163.com
- Phone: +8615010305099
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.